A Scientific and Laboratory Complex started its work in the Lefortovo branch of the Federal State Unitary Enterprise “Endopharm” on Laboratornaya Street.
On March 22, Mikhail Fonarev, Director General of FSUE Endopharm, reported on the completion of the project for Complex reconstruction and technical re-equipment to Vasily Os’makov, First Deputy Minister of Industry and Trade of the Russian Federation, and Sergey Sobyanin, Mayor of Moscow, at the official opening ceremony of the Complex.
The new scientific and laboratory complex, with an area of about 7 thousand square meters, comprises a production site for active pharmaceutical ingredients, a pilot production site for the medicines, a site for the development and production of reference materials, as well as analytical laboratories and laboratories for the development and transfer of advanced technologies of producing finished medicinal products.
“944 million rubles were invested in the project implementation. The commissioning of the scientific and laboratory building was the next stage in the creation of a large industrial cluster in the Lefortovo branch for the development and production of full-cycle medicines,” commented Dmitry Averyanov, Deputy Director General, Director of the Lefortovo branch of FSUE Endopharm.
The total investment in the development of the Lefortovo branch is 9.9 billion rubles, of which 6.6 billion rubles are at the Enterprise’s own expense. The commissioning in 2025 of a large production complex for the production of finished medicines will be the next stage in the development of the branch.
“The Enterprise ensures the defect-free availability of produced narcotic and psychotropic drugs and fulfills obligations to provide all regions of the Russian Federation with these drugs in accordance with the Distribution Plan approved by the Ministry of Industry and Trade of Russia. Our task is to ensure that the entire line of produced drugs are available to the consumer, including in the conditions of unpredictable international market relations. Large-scale production of active pharmaceutical ingredients and the cultivation of plant materials are organized in the branches located in the Bryansk region, in order to fully localize the production of socially significant pain-relieving medicines in the country. The production of our own substance of chorionic gonadotropin is also one of the priorities today, so as to organize a full production cycle of a medicine that is in high demand in the treatment of a number of diseases of the reproductive system in women and men. Production sites in Moscow ensure the implementation of innovative developments and the production of finished dosage forms,” said Mikhail Fonarev, Director General of FSUE Endopharm.
Vasily Os’makov, First Deputy Minister of Industry and Trade of the Russian Federation, noted that FSUE Endopharm significantly contributed to ensuring national drug safety and technological sovereignty of the country.
“The opening of a modern R&D complex today is a vivid confirmation of this. This is one of the stages of a large-scale investment project for technical re-equipment of production facilities, which is being implemented with the support of the Ministry of Industry and Trade of Russia. As a result, by 2025, a powerful industrial complex with modern research and laboratory facilities will be built. The Ministry of Industry and Trade, for its part, will continue to render all the necessary support to the enterprise. The amount of government support for the plant has totalled to almost 4 billion rubles over the past three years,” said the First Deputy Head of the Ministry of Industry and Trade of Russia.
FSUE Endopharm has expanded its expertise in the development and production of reference materials, which can reduce dependence on imports and the time for medicine trials, he added. More than half of reference materials produced by the enterprise are designed to control the quality of medicines included in the list of Vital and Essential Drugs.
The opening of the new complex made it possible to create more than 280 new high-tech jobs in Moscow.
“The Moscow Endocrine Plant is the largest pharmaceutical enterprise in Moscow and plays a key role in the healthcare system as the largest manufacturer of pain-relieving medicines. The plant’s products are consistently supplied to pharmacies and medical institutions of the city. Moreover, in 2021 we signed an offset contract under which the Moscow Endocrine Plant invested in the renewal of production facilities, and the Moscow Government assumed obligations to guarantee the purchase of a certain amount of medicines in demand. The investor has fulfilled its obligations and will start deliveries by offset this month,” noted Sergey Sobyanin.
Since 2016, FSUE Endopharm has the status of “Industrial Complex”, which allows the Enterprise to receive municipal tax benefits and direct additional funds to new scientific developments.
At the end of the event, the Director General of FSUE Endopharm thanked the Ministry of Industry and Trade of Russia, the Moscow Mayor’s Office and the prefecture of the Eastern Administrative District of Moscow for the support provided to the enterprise.
Vasily Os’makov, First Deputy Minister of Industry and Trade of the Russian Federation, and Sergey Sobyanin, Mayor of Moscow, in their turn, congratulated the staff of FSUE Endopharm on the successful implementation of the project in the Lefortovo branch and on the 80th anniversary of the enterprise, which is celebrated this year.
Comment type is not specified in the component properties.